What is the latest evidence-based thinking on the management of upper-tract urothelial cancer (UTUC)? In this lively roundtable discussion, three leading experts review and discuss key practical issues. They provide insights into current challenges in UTUC management, along with updates on staging, grading, and risk stratification for identification of patients who are candidates for kidney-sparing approaches. The experts also discuss recent clinical efficacy and safety data on chemoablation for low-grade UTUC and the risk/benefit profile in relation to traditional surgical treatments, offering a rationale for the use of each of these approaches in candidate patients.
This activity is supported by an independent educational grant from UroGen Pharma, Inc.